Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | ABSK061 |
Synonyms | |
Therapy Description |
ABSK061 inhibits FGFR2 and FGFR3, potentially leading to antitumor activity (ESMO Open 9 (2024): 102274). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ABSK061 | ABSK-061|ABSK 061 | FGFR2 Inhibitor 23 FGFR3 Inhibitor 19 | ABSK061 inhibits FGFR2 and FGFR3, potentially leading to antitumor activity (ESMO Open 9 (2024): 102274). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
FGFR3 fusion | transitional cell carcinoma | predicted - sensitive | ABSK061 | Case Reports/Case Series | Actionable | In a Phase I trial, ABSK061 treatment resulted in a partial response in a patient with urothelial carcinoma harboring an FGFR3 fusion (ESMO Open 9 (2024): 102274); NCT05244551). | detail... |
FGFR2 fusion | lung non-small cell carcinoma | predicted - sensitive | ABSK061 | Case Reports/Case Series | Actionable | In a Phase I trial, ABSK061 treatment resulted in a partial response in a patient with non-small cell lung cancer harboring an FGFR2 fusion (ESMO Open 9 (2024): 102274); NCT05244551). | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05244551 | Phase I | ABSK061 | A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK061 in Patients With Advanced Solid Tumors | Recruiting | USA | 1 |